Rhenium-186 [t½ = 3.7 d, 1.07 MeV β−-particles, 137 keV γ-ray] is an emerging radioisotope which holds tremendous potential in preparation of theranostic radiopharmaceuticals. This radioisotope was produced in a no-carrier-added form by irradiation of enriched 186W target via 186W(p, n) 186Re reaction in a pelletron. A facile radiochemical separation procedure based on selective solvent extraction in methylethyl ketone medium followed by column chromatography using mesoporous alumina sorbent has been developed to obtain 186Re in a form suitable for radiopharmaceutical preparation. This approach is expected to promote widespread utilization of this radioisotope for the benefit of cancer patients.

中文翻译：

---

质子辐照钨靶中无载流子 186Re 的放射化学分离

Rhenium-186 [t½ = 3.7 d, 1.07 MeV β-粒子, 137 keV γ 射线] 是一种新兴的放射性同位素，在制备治疗诊断放射性药物方面具有巨大潜力。这种放射性同位素是通过 186W(p, n) 186Re 反应在颗粒管中通过辐照富集的 186W 靶材以不添加载体的形式产生的。基于在甲基乙基酮介质中选择性溶剂萃取然后使用介孔氧化铝吸附剂进行柱色谱的简便放射化学分离程序已被开发，以获得适合放射性药物制备形式的 186Re。这种方法有望促进这种放射性同位素的广泛利用，以造福癌症患者。